The development of the new cancer virus, cell therapy for ovarian cancer and the analysis of immune system response

我们已经开发了复制能力，减毒单纯疱疹病毒-1（HSV-1）突变体，已被评估其溶瘤活性。然而，宿主免疫系统仍然是在临床环境中有效腹膜内施用这些病毒的显著障碍。在这项研究中，我们研究了使用这些HSV-1突变体作为溶瘤剂对卵巢癌和人腹膜间皮细胞作为载体细胞腹腔内治疗。我们的研究结果表明，这些HSV-1突变体对卵巢癌发挥了有效的溶瘤作用，这可能会进一步增强利用载体细胞递送系统，基于病毒载量的扩增和可能避免中和抗体。

We have developed replication-competent, attenuated herpes simplex virus-1(HSV-1) mutants, which have been evaluated for their oncolytic activities. However, the host immune system remains a significant obstacle to effective intraperitoneal administration of these viruses in the clinical setting. In this study, we investigated the use of these HSV-1 mutants as oncolytic agents against ovarian cancer and human peritoneal mesothelial cells as carrier cells for intraperitoneal therapy. Our results indicate that these HSV-1 mutants exerts a potent oncolytic effect on ovarian cancer, which may be further enhanced by the utilization of a carrier cell delivery system, based on amplification of viral load and possibly on avoidance of neutralizing antibodies.